On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA Administrative Law Judge (ALJ) hearing that could determine whether adult-use cannabis joins state-licensed medical cannabis on Schedule III of the Controlled Substances Act, begins proceedings.
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
The Trump administration’s continued inaction on its promise to push ahead with the highly anticipated cannabis rescheduling project is now presenting some real-world issues for many of the sector’s largest players.
Cannabis Rescheduling fervour has once again reached dramatic levels following media reports that President Donald Trump is considering pushing through the long-touted move via an executive order.
US cannabis companies have endured a significant selloff in the days following the results of the election, seeing $2.6bn wiped off their collective market capitalization.
Cannabis stocks plunge on election results As the outcome of the US presidential election and numerous state-specific cannabis ballots dripped through yesterday, the markets reacted in tandem.
Florida based cannabis giant Trulieve has agreed to pay a settlement fine of $350,000 following the death of one of its workers in 2022.
This week, a swathe of North America’s largest cannabis companies reported thier most recent financial results, revealing slimming but continued losses almost unanimously.
The US Drug Enforcement Administration (DEA) has confirmed that it is conducting a review into the reclassification of cannabis, but has asserted its ‘final authority’ over the decision.
